Halberd Corporation Files for Patent Protection on Enhanced Nasal Spray to Prevent Covid-19
Halberd Corporation reported the filing of a Covid-19 provisional patent on an enhanced nasal spray. The application, Nasal Spray to Prevent the Transmission of Covid-19, discloses a combination of proprietary Covid-19 Spike Protein antibodies, ACE2 antibody, and Neuropilin-1 antibodies. This application builds on, and is an improvement to an earlier provisional patent application, Nasal Spray to Prevent the Transmission of Covid-19 Between Humans.
Multiple medical articles (1, 2) have shown that intra-nasal ACE2 receptors, which are more prevalent in older adults than children, are thought to be a key factor in adults being infected with Covid-19 at higher rates than children. Recent studies have shown Neuropilin-1, a protein widespread in the body, but occurring primarily on cells in the lungs and nose (3), provides additional binding sites for the Covid-19 spike protein. By blocking ACE2 receptors and Neuropilin-1, it is believed Covid-19 spike proteins can be prevented from attaching to receptors in nasal passages, and reducing the disease’s infectivity (4).
Mr. William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated “As more becomes known about the Covid-19 virus, the better we are able to configure our treatments to combat the disease. This new intellectual property is a case in point. This second nasal spray configuration, which builds on the initial design, we believe will provide enhanced protection against contracting Covid-19 by preventing access through nasal receptors.”
The details of the Halberd-ASU research contract can be viewed here.
Halberd Corporation is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt, which would result in dilution. See the company’s Articles of Incorporation here.
HalberdCorporation is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: Method for Treating and Curing Covid-19 Infection; Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients; and Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus. Halberd also holds exclusive rights to two Covid-19 nasal spray provisional patents: Nasal Spray to Prevent the Transmission of Covid-19 Between Humans, and Nasal Spray to Prevent the Transmission of Covid-19.
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
www.halberdcorporation.com
Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Total Page Views: 1654
